PT3191139T - Terapia do gene rpgr para retinite pigmentosa - Google Patents

Terapia do gene rpgr para retinite pigmentosa

Info

Publication number
PT3191139T
PT3191139T PT158253831T PT15825383T PT3191139T PT 3191139 T PT3191139 T PT 3191139T PT 158253831 T PT158253831 T PT 158253831T PT 15825383 T PT15825383 T PT 15825383T PT 3191139 T PT3191139 T PT 3191139T
Authority
PT
Portugal
Prior art keywords
gene therapy
retinitis pigmentosa
rpgr gene
rpgr
pigmentosa
Prior art date
Application number
PT158253831T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Massachusetts Eye & Ear Infirmary
Ucl Business Ltd
The Government Of The Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, Ucl Business Ltd, The Government Of The Us Secretary Department Of Health And Human Services filed Critical Massachusetts Eye & Ear Infirmary
Publication of PT3191139T publication Critical patent/PT3191139T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT158253831T 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa PT3191139T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
PT3191139T true PT3191139T (pt) 2020-11-05

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
PT158253831T PT3191139T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa
PT201992088T PT3821912T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT201992088T PT3821912T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Country Status (18)

Country Link
US (2) US10314924B2 (cg-RX-API-DMAC7.html)
EP (2) EP3821912B1 (cg-RX-API-DMAC7.html)
JP (3) JP6654760B2 (cg-RX-API-DMAC7.html)
CN (1) CN107206105A (cg-RX-API-DMAC7.html)
CA (1) CA2991750C (cg-RX-API-DMAC7.html)
CY (1) CY1123793T1 (cg-RX-API-DMAC7.html)
DK (2) DK3821912T3 (cg-RX-API-DMAC7.html)
ES (2) ES2834402T3 (cg-RX-API-DMAC7.html)
FI (1) FI3821912T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20202023T1 (cg-RX-API-DMAC7.html)
HU (2) HUE052781T2 (cg-RX-API-DMAC7.html)
LT (2) LT3821912T (cg-RX-API-DMAC7.html)
PL (2) PL3821912T3 (cg-RX-API-DMAC7.html)
PT (2) PT3191139T (cg-RX-API-DMAC7.html)
RS (2) RS65909B1 (cg-RX-API-DMAC7.html)
SI (2) SI3821912T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000715T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016014353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6654760B2 (ja) * 2014-07-24 2020-02-26 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜色素変性症のためのｒｐｇｒ遺伝子治療
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
EP3719134B1 (en) 2015-03-11 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
WO2019077159A1 (en) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
RS65881B1 (sr) * 2017-11-15 2024-09-30 Univ Michigan Regents Virusni vektori koji sadrže kodirajuće regione rdh12 i postupci za lečenje distrofija mrežnjače
IL296262A (en) * 2020-03-11 2022-11-01 Massachusetts Eye & Ear Infirmary Gene therapy for nmnat1-related retinal degeneration
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
CA2095256A1 (en) 1990-10-31 1992-05-01 Brad Guild Retroviral vectors useful for gene therapy
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
WO2001038578A1 (en) * 1999-11-24 2001-05-31 Cornell Research Foundation, Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) * 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
CN105120901A (zh) 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
JP6654760B2 (ja) * 2014-07-24 2020-02-26 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜色素変性症のためのｒｐｇｒ遺伝子治療

Also Published As

Publication number Publication date
EP3821912B1 (en) 2024-06-12
JP2022009333A (ja) 2022-01-14
RS61307B1 (sr) 2021-02-26
JP6654760B2 (ja) 2020-02-26
CN107206105A (zh) 2017-09-26
CY1123793T1 (el) 2022-05-27
EP3191139A4 (en) 2018-01-10
SMT202000715T1 (it) 2021-01-05
HRP20202023T1 (hr) 2021-03-05
SMT202400309T1 (it) 2024-11-15
FI3821912T3 (fi) 2024-08-05
EP3191139A1 (en) 2017-07-19
LT3821912T (lt) 2024-09-25
DK3191139T3 (da) 2020-11-16
CA2991750A1 (en) 2016-01-28
CA2991750C (en) 2023-02-14
HUE068183T2 (hu) 2024-12-28
JP2020073536A (ja) 2020-05-14
LT3191139T (lt) 2021-01-25
US20170216454A1 (en) 2017-08-03
JP2017523239A (ja) 2017-08-17
WO2016014353A1 (en) 2016-01-28
ES2834402T3 (es) 2021-06-17
US20200215203A1 (en) 2020-07-09
SI3821912T1 (sl) 2024-10-30
EP3821912A1 (en) 2021-05-19
JP7198329B2 (ja) 2022-12-28
DK3821912T3 (da) 2024-08-05
US10314924B2 (en) 2019-06-11
RS65909B1 (sr) 2024-10-31
US11045558B2 (en) 2021-06-29
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
EP3191139B1 (en) 2020-10-07
HUE052781T2 (hu) 2021-05-28
SI3191139T1 (sl) 2021-03-31
PL3821912T3 (pl) 2024-10-28
JP6966532B2 (ja) 2021-11-17
ES2987090T3 (es) 2024-11-13
HRP20241154T1 (hr) 2024-11-22

Similar Documents

Publication Publication Date Title
IL284741B (en) Gene therapy for retinitis pigmentosa
IL304084B1 (en) Gene healing
GB201420139D0 (en) Factor IX gene therapy
HUE068183T2 (hu) RPGR génterápia a retinitis pigmentosa terápiájára
GB201407322D0 (en) Gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201701968D0 (en) Gene therapy
GB201513151D0 (en) Functional gene replacement therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201704634D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition
GB201410595D0 (en) Factor IX gene therapy